Svoboda | Graniru | BBC Russia | Golosameriki | Facebook

Effects of Helicobacter pylori infection on intestinal microbiota, immunity and colorectal cancer risk

Front Cell Infect Microbiol. 2024 Jan 26:14:1339750. doi: 10.3389/fcimb.2024.1339750. eCollection 2024.

Abstract

Infecting about half of the world´s population, Helicobacter pylori is one of the most prevalent bacterial infections worldwide and the strongest known risk factor for gastric cancer. Although H. pylori colonizes exclusively the gastric epithelium, the infection has also been associated with various extragastric diseases, including colorectal cancer (CRC). Epidemiological studies reported an almost two-fold increased risk for infected individuals to develop CRC, but only recently, direct causal and functional links between the chronic infection and CRC have been revealed. Besides modulating the host intestinal immune response, H. pylori is thought to increase CRC risk by inducing gut microbiota alterations. It is known that H. pylori infection not only impacts the gastric microbiota at the site of infection but also leads to changes in bacterial colonization in the distal large intestine. Considering that the gut microbiome plays a driving role in CRC, H. pylori infection emerges as a key factor responsible for promoting changes in microbiome signatures that could contribute to tumor development. Within this review, we want to focus on the interplay between H. pylori infection, changes in the intestinal microbiota, and intestinal immunity. In addition, the effects of H. pylori antibiotic eradication therapy will be discussed.

Keywords: Helicobacter pylori; antibiotics; colorectal cancer; eradication therapy; immune response; intestinal microbiome.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Colorectal Neoplasms* / epidemiology
  • Colorectal Neoplasms* / etiology
  • Gastrointestinal Microbiome*
  • Helicobacter Infections* / complications
  • Helicobacter Infections* / microbiology
  • Helicobacter pylori* / physiology
  • Humans
  • Stomach / microbiology

Substances

  • Anti-Bacterial Agents

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. DFG GE 2042_21-1, Project number 535013688.